Abstract
Fragile X syndrome (FXS) is associated with a characteristic profile of physical and neurobehavioral abnormalities. These phenotypical features are highly variable among affected individuals, which leads to difficulties in developing and evaluating treatments as well as in determining accurate prognosis. The current investigation employed data from FORWARD, a clinic-based natural history study of FXS, to identify subtypes by applying latent class analysis (LCA).
A pediatric cross-sectional sample of 1,072 males and 338 females was subjected to LCA to identify neurobehavioral classes (groups). Input consisted of multiple categorical and continuous cognitive and behavioral variables, including co-occurring behavioral conditions, sleep and sensory problems, measures of autistic behavior (SCQ, SRS-2), and scores on the Aberrant Behavior Checklist revised for FXS (ABCFX). Clinically relevant class solutions were further delineated by identifying predictors using stepwise logistic regressions and pairwise comparisons. Following this, classes were characterized in terms of key demographic, genetic, and clinical parameters.
LCA fit parameters supported 2- to 6-class models, which showed good correspondence between patterns of co-occurring conditions and scores on standardized measures. The 5-class solution yielded the most clinically meaningful characterization of groups with unique cognitive and behavioral profiles. The “Mild” class (31%) included patients with attention problems and anxiety but few other major behavioral challenges as reflected by scale scores. Most individuals in the “Severe” class (9%) exhibited multiple co-occurring conditions and high mean scale scores on behavioral measures. Three “Moderate” classes were identified: a “Moderate Behavior” class (32%), a “Social Impairment” class (7%), and a “Disruptive Behavior” class (20%). All classes displayed distinctive SRS-2, SCQ, and ABCFX profiles, which reflected their degree of non-overlap as estimated by pairwise effect sizes. Groups differed with regard to sex, intellectual disability, autism spectrum disorder diagnosis, and medication use.
These findings support the notion that, it is possible to identify behavioral subtypes in children with FXS, reflecting both overall level of severity and specific areas of impairment. These subtypes have implications for clinical management and therapeutic development and assessment. Future studies are needed to determine the stability of these group profiles and their relationship with other aspects of the FXS phenotype.
Competing Interest Statement
WEK is Chief Scientific Officer of Anavex Life Sciences Corp. HKH is a co-investigator on clinical trials funded by Ionis Pharmaceuticals, Neuren Pharmaceuticals and Clinical Research Associates, LLC. DBB has been principal investigator on clinical trials funded by Ovid Therapeutics and Zynerba Pharmaceuticals; he has also consulted for Ovid Therapeutics. The other co-authors declare that they have no competing interests.
Funding Statement
Centers for Disease Control and Prevention
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Emory University School of Medicine, 615 Michael Street, Atlanta GA 30322, USA. RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA. Texas Children's Hospital, 8080 North Stadium Drive, Houston, TX 77054, USA. Kennedy Krieger Institute, 1741 Ashland Avenue, Baltimore, MD 21205, USA. Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. Ethics approval and consent to participate The Institutional Review Board at every participating site provided approval and oversight to ensure ethical conduct of human subjects research throughout the study. Informed consent was provided by all parents/guardians who participated. Consent or assent was provided by participants with fragile X syndrome, depending on age and consenting capacity as determined by the Institutional Review Boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data are available according to the FORWARD project's Data Sharing Plan and the policies of the Centers for Disease Control and Prevention.
Abbreviations
- FXS
- Fragile X syndrome
- LCA
- Latent class analysis
- SCQ
- Social Communication Questionnaire
- SRS-2
- Social Responsiveness Scale-2
- ABCFX
- Aberrant Behavior Checklist revised for FXS
- FMRP
- Fragile X Mental Retardation Protein
- (ID)
- intellectual disability
- ADHD
- Attention-deficit/hyperactivity disorder
- ASD
- Autism spectrum disorder
- IAAS
- Irritability/agitation, aggression, and self-injury
- SD
- Standard Deviation
- AIC
- Akaike information criterion
- BIC
- Bayesian information criterion.